about
IL-22 and IDO1 affect immunity and tolerance to murine and human vaginal candidiasisA polysaccharide virulence factor from Aspergillus fumigatus elicits anti-inflammatory effects through induction of Interleukin-1 receptor antagonistDectin-1 isoforms contribute to distinct Th1/Th17 cell activation in mucosal candidiasis.Distinct and complementary roles for Aspergillus fumigatus-specific Tr1 and Foxp3+ regulatory T cells in humans and mice.Microbiota control of a tryptophan-AhR pathway in disease tolerance to fungi.CD4(+) T cell vaccination overcomes defective cross-presentation of fungal antigens in a mouse model of chronic granulomatous disease.IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosisProvision of antifungal immunity and concomitant alloantigen tolerization by conditioned dendritic cells in experimental hematopoietic transplantation.IL-17 and therapeutic kynurenines in pathogenic inflammation to fungi.Indoleamine 2,3-dioxygenase (IDO) in inflammation and allergy to Aspergillus.Th17 cells in the setting of Aspergillus infection and pathology.IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans.Non-hematopoietic cells contribute to protective tolerance to Aspergillus fumigatus via a TRIF pathway converging on IDO.Thymosin alpha1: the regulator of regulators?IL-22 in antifungal immunity.Tryptophan Feeding of the IDO1-AhR Axis in Host-Microbial Symbiosis.Th17/Treg imbalance in murine cystic fibrosis is linked to indoleamine 2,3-dioxygenase deficiency but corrected by kynurenines.The IL-17F/IL-17RC Axis Promotes Respiratory Allergy in the Proximal Airways.Pathogenic NLRP3 Inflammasome Activity during Candida Infection Is Negatively Regulated by IL-22 via Activation of NLRC4 and IL-1Ra.Intranasally delivered siRNA targeting PI3K/Akt/mTOR inflammatory pathways protects from aspergillosis.Inflammation in aspergillosis: the good, the bad, and the therapeutic.Hypoxia promotes danger-mediated inflammation via receptor for advanced glycation end products in cystic fibrosis.High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway.Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22.IL-17/Th17 in anti-fungal immunity: what's new?Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease.Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and IDO-dependent inhibition of Rorc.Leucine-Rich Repeat Kinase 2 Controls the Ca2+/Nuclear Factor of Activated T Cells/IL-2 Pathway during Aspergillus Non-Canonical Autophagy in Dendritic Cells.TLR3 essentially promotes protective class I-restricted memory CD8⁺ T-cell responses to Aspergillus fumigatus in hematopoietic transplanted patients.IL-22 defines a novel immune pathway of antifungal resistance.Exogenous pentraxin 3 restores antifungal resistance and restrains inflammation in murine chronic granulomatous disease.RT-qPCR detection of Aspergillus fumigatus RNA in vitro and in a murine model of invasive aspergillosis utilizing the PAXgene® and Tempus™ RNA stabilization systems.Sensing of mammalian IL-17A regulates fungal adaptation and virulence.Towards Targeting the Aryl Hydrocarbon Receptor in Cystic Fibrosis.Autophagy and LAP in the Fight against Fungal Infections: Regulation and Therapeutics.A GpC-Rich Oligonucleotide Acts on Plasmacytoid Dendritic Cells To Promote Immune SuppressionIL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance
P50
Q28534626-6D8DC657-E78E-4182-92F4-548C8C562F6FQ28540595-1F4B2FB2-4090-47E7-AA5E-DF16D35A9EC4Q33577398-572381F1-7BDC-4DD3-9DD8-A3DF1281A900Q34207966-3A843484-1F57-455D-9EE6-3BE9B9CC43DDQ35277854-0AD9632B-4E12-44EF-ABF3-2E30D097C113Q35913715-8DE5633F-6FE5-4191-A4E4-665633FDBD15Q36690556-046D3F7A-B8D3-43F8-BEBC-A651D6C1F701Q36934952-D6C1F389-6E22-49F2-8E4A-4223BE8957E0Q37129200-CA97D9A8-0848-477B-A5E7-F68AB1CD3517Q37209953-8734878D-F026-460A-B2EE-AEB3FAE0A635Q37209967-28BA4912-3FE9-4BFA-B0F4-DF799530E564Q37627905-8E91A02C-0A11-4A49-BCBE-D4E3130610ACQ37729196-1E9A68AE-0523-430E-93E9-F18530DE1EABQ37763964-DD34A446-519C-4518-9D5E-B11229D55133Q37832449-F08D17BB-1E89-43FE-A7DD-6812430D281EQ38310249-8589BD20-3409-4088-AE46-0238271CF93BQ39488014-A660D19C-EF40-4C25-A24B-10B71106371EQ40091376-9731DA87-E9D4-4D0A-A1D6-43903D8A0263Q41054725-889C8A08-0DA9-4D16-8F22-8E6C1AEDC42BQ43239054-7FF6CD40-7748-4AC9-8B90-44A40A1C9020Q44902285-59230D21-B4CB-4859-A5EA-C50CB07CCCCAQ44909879-9E53B1F1-FA6D-4475-B5BF-29217A073CE1Q45163458-3EC1A0D4-8BE4-4049-8270-813FF70CA11EQ45760347-C836C482-B63D-447C-88EC-BD706409F270Q46089935-A0F36E99-D7DA-43C9-8D5B-D12411BAC504Q46815296-6F6F4974-02DD-4808-80FA-8F099F1156D7Q46942144-5D9C2029-CB50-4FE9-B756-1E6A6635F064Q50190181-A4AF2E47-34F1-4EE0-BB88-83E79956AF59Q50979376-B588F423-707E-433B-8097-0D035B835819Q51054891-485FE0B1-A900-4F82-8AEE-399E4FA38DDFQ51777315-90F3E106-05CE-4058-8FE6-3A835B029F50Q54328149-4B7394A4-615E-41C6-B748-1EB8BA0D2744Q54528212-DC44C2D4-3287-49C2-8346-10EE940F8AE4Q54958046-79B4387D-3453-4AC8-81AE-A36A1A7CD4D5Q54959388-A1D2C1A0-92A9-43EA-82ED-F0ACAB142E48Q58855369-D4264802-FF4E-4830-B486-DA597864B5A3Q58855387-12E5C023-D657-4BCA-8F13-C5225D5172B1
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-6866-5530
@en
name
Antonella De Luca
@ast
Antonella De Luca
@en
Antonella De Luca
@es
Antonella De Luca
@nl
type
label
Antonella De Luca
@ast
Antonella De Luca
@en
Antonella De Luca
@es
Antonella De Luca
@nl
prefLabel
Antonella De Luca
@ast
Antonella De Luca
@en
Antonella De Luca
@es
Antonella De Luca
@nl
P106
P21
P31
P496
0000-0002-6866-5530